These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 25390030)

  • 1. Sensitivity analysis of methods for active surveillance of acute myocardial infarction using electronic databases.
    Li X; Girman CJ; Ofner S; Shen C; Brodovicz KG; Simonaitis L; Santanello N
    Epidemiology; 2015 Jan; 26(1):130-2. PubMed ID: 25390030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent.
    Fireman B; Toh S; Butler MG; Go AS; Joffe HV; Graham DJ; Nelson JC; Daniel GW; Selby JV
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():282-90. PubMed ID: 22262618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study.
    Horsdal HT; Søndergaard F; Johnsen SP; Rungby J
    Pharmacoepidemiol Drug Saf; 2011 Apr; 20(4):331-7. PubMed ID: 21442682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study.
    Horsdal HT; Mehnert F; Rungby J; Johnsen SP
    J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):717-25. PubMed ID: 21536457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronary heart disease outcomes in patients receiving antidiabetic agents.
    McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
    Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA).
    Meier JJ; Deifuss S; Klamann A; Schmiegel W; Nauck MA;
    Exp Clin Endocrinol Diabetes; 2003 Sep; 111(6):344-50. PubMed ID: 14520601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the impact of propensity score estimation and implementation on covariate balance and confounding control within and across important subgroups in comparative effectiveness research.
    Girman CJ; Gokhale M; Kou TD; Brodovicz KG; Wyss R; Stürmer T
    Med Care; 2014 Mar; 52(3):280-7. PubMed ID: 24374422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.
    Rascati K; Richards K; Lopez D; Cheng LI; Wilson J
    Diabetes Obes Metab; 2013 Oct; 15(10):901-5. PubMed ID: 23531154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of fasting blood glucose levels and blood pressure and treatment of diabetes and hypertension on the incidence of cardiovascular disease: a study of 740 patients with incident Type 2 diabetes with up to 30 years' follow-up.
    Jansson SP; Svärdsudd K; Andersson DK
    Diabet Med; 2014 Sep; 31(9):1055-63. PubMed ID: 24894815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
    Johannes CB; Koro CE; Quinn SG; Cutone JA; Seeger JD
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007.
    Walker AM; Koro CE; Landon J
    Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):760-8. PubMed ID: 18383443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression to insulin for patients with diabetes mellitus using the Texas Medicaid database.
    Rascati KL; Richards KM; Lopez D; Cheng LI; Wilson JP
    Clin Ther; 2011 Dec; 33(12):2016-20. PubMed ID: 22101160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
    Thakkar B; Aronis KN; Vamvini MT; Shields K; Mantzoros CS
    Metabolism; 2013 Jul; 62(7):922-34. PubMed ID: 23419783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Summaries for patients. How do older diabetes drugs compare in their effects on heart and blood vessel disease?
    Ann Intern Med; 2012 Nov; 157(9):I-28. PubMed ID: 23128878
    [No Abstract]   [Full Text] [Related]  

  • 16. Quantifying the impact of drug exposure misclassification due to restrictive drug coverage in administrative databases: a simulation cohort study.
    Gamble JM; McAlister FA; Johnson JA; Eurich DT
    Value Health; 2012 Jan; 15(1):191-7. PubMed ID: 22264988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Diabetes Obes Metab; 2012 Sep; 14(9):803-9. PubMed ID: 22486923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus.
    Brown JB; Nichols GA; Glauber HS; Bakst A
    Clin Ther; 1999 Jun; 21(6):1045-57. PubMed ID: 10440626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study.
    Horsdal HT; Johnsen SP; Søndergaard F; Jacobsen J; Thomsen RW; Schmitz O; Sørensen HT; Rungby J
    Diabetes Metab Res Rev; 2009 Sep; 25(6):515-22. PubMed ID: 19459168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.
    Vaccaro O; Masulli M; Bonora E; Del Prato S; Giorda CB; Maggioni AP; Mocarelli P; Nicolucci A; Rivellese AA; Squatrito S; Riccardi G;
    Nutr Metab Cardiovasc Dis; 2012 Nov; 22(11):997-1006. PubMed ID: 23063367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.